These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34364728)

  • 21. Re: Mathieu Rouanne, Dean F. Bajorin, Raquibul Hannan, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol 2020;3:728-38.
    Montorsi F; Martini A
    Eur Urol Oncol; 2021 Apr; 4(2):336. PubMed ID: 33541839
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
    Cheng C; Hu J; Chen J
    Eur Urol; 2023 Jun; 83(6):e159-e160. PubMed ID: 36967357
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9.
    Teoh JY; Murphy DG; van Oort IM; Loeb S; Ribal MJ
    Eur Urol; 2021 Oct; 80(4):e101. PubMed ID: 34315625
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306.
    Panebianco V; Barentsz J; Narumi Y; Catto JWF
    Eur Urol; 2019 Feb; 75(2):e29-e30. PubMed ID: 30471881
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. Eur Urol Oncol 2020;7:739-47.
    Morka N; Simpson BS; Emberton M; Norris JM
    Eur Urol Oncol; 2021 Feb; 4(1):127-128. PubMed ID: 33509743
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260-1.
    Bessa A; Maclennan S; Enting D; Bryan R; Häggström C; Van Hemelrijck M
    Eur Urol; 2019 Aug; 76(2):e45-e46. PubMed ID: 31109813
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Choi W; McConkey D
    Eur Urol; 2018 Apr; 73(4):e104-e105. PubMed ID: 29174465
    [No Abstract]   [Full Text] [Related]  

  • 28. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder Cancer.
    Vetterlein MW; Gild P; Fisch M; Rink M
    Eur Urol; 2020 Aug; 78(2):e77-e78. PubMed ID: 32376138
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105-11.
    Cardona Ortegón JD; Campaña Perilla LA; Olarte Bermúdez LM
    Eur Urol; 2024 Jul; 86(1):e21. PubMed ID: 38644137
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
    Van Allen EM; Garraway LA; Rosenberg JE
    Eur Urol; 2015 Aug; 68(2):e31-2. PubMed ID: 25770487
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016.
    Iyer G; Bochner BH; Van Allen EM; Solit DB; Rosenberg JE
    Eur Urol; 2021 Feb; 79(2):e56-e57. PubMed ID: 33218823
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Nicola Nicolai, Rosalba Miceli, Andrea Necchi, et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol 2010;58:912-8.
    Akyol I; Soydan H; Ates F
    Eur Urol; 2011 Apr; 59(4):e20; author reply e21-2. PubMed ID: 21255907
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to Jonathan Aning, Paul McCoubrie, and Jon Oxley's Letter to the Editor re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. Eur Urol 2020;77:733-41.
    Gandaglia G; Montorsi F; Briganti A
    Eur Urol; 2020 Nov; 78(5):e200. PubMed ID: 32800726
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
    Garg M; Goel A; Prakash J
    Eur Urol; 2013 Jan; 63(1):e6. PubMed ID: 23021089
    [No Abstract]   [Full Text] [Related]  

  • 35. [Neoadjuvant chemotherapy with MVAC in bladder carcinoma: Is the feasibility really established? Of: Benadiba et al.: Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences on cystectomy, Pr Urol 2015; 25: 549-554].
    Coquard R
    Prog Urol; 2015 Dec; 25(16):1171-2. PubMed ID: 26420677
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4.
    Lu M; Zhang Y; Xiao Y
    Eur Urol; 2019 Nov; 76(5):e135-e136. PubMed ID: 31420251
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Edwin E. Morales, Sonja Grill, Robert S. Svatek, et al. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol 2016;69:407-10.
    Kim JH; Ku JH
    Eur Urol; 2016 Mar; 69(3):e57-8. PubMed ID: 26683757
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.
    Safiri S; Ayubi E
    Eur Urol; 2017 Sep; 72(3):e63. PubMed ID: 28648368
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Guido Dalbagni, Kinjal Vora, Matthew Kaag, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009;56:903-10.
    Bultitude M; O'Brien T
    Eur Urol; 2010 Apr; 57(4):e39-40; author reply e41-2. PubMed ID: 20089350
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Guido Dalbagni, Kinjal Vora, Matthew Kaag, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009;56:903-10.
    Cai T; Bartoletti R
    Eur Urol; 2010 Apr; 57(4):e38. PubMed ID: 20061076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.